Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 1/2019

01-01-2019 | Review – Cancer Research

Multiple functions of HuR in urinary tumors

Authors: Fa Zhang, Zhonglin Cai, Haidi Lv, Wenjuan Li, Mengtian Liang, Xupan Wei, Fenghai Zhou

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2019

Login to get access

Abstract

Purpose

Human embryonic lethal abnormal visual-like protein, HuR, belongs to a member of the Hu family of RNA-binding protein and plays a critical role in urinary tumors. The purpose of this review is to summarize the current literature to demonstrate the importance of HuR in urinary tract tumors’ biology and explore the potential role in therapeutic strategies aimed at targeting this molecule in cancer cells.

Methods

The relevant literature from PubMed and Medline databases is reviewed in this article.

Results

Increasing evidence supports that HuR plays a critical role in urinary tumors’ biology because it regulates the expression of many urinary tumors-associated molecules through post-transcriptional regulatory mechanisms (including mRNA trafficking, mRNA decay and protein translation). Recent studies have demonstrated that HuR is associated with chemoresistance of urinary tumors, suggesting that HuR might be a novel therapeutic target and a marker for therapeutic response and prognosis assessment.

Conclusion

HuR is associated with various urinary tumors biological characteristics. Targeted therapy of HuR may become an attractive treatment strategy. What’s more, more preclinical and clinical trials of this targeted strategy are necessary for the treatment of urinary tumors.
Literature
Annabi B, Bouzeghrane M, Currie JC (2006) Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs 17(4):429–438CrossRefPubMed
Barbisan F, Mazzucchelli R, Santinelli A (2009) Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 56(1):105–112CrossRefPubMed
Basu A, Datta D, Zurakowski D (2010) Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem 13(33):25196–25202 285(CrossRef
Cathomas R, De Santis M, Galsky MD (2015) First-line treatment of metastatic disease: cisplatin-ineligible patients. Hematol Oncol Clin N Am 29(2):329–340, xCrossRef
Cha JD, Li S, Cha IH (2011) Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma. Head Neck 33(5):627–637CrossRefPubMed
Chae KS, Kang MJ, Lee JH (2011) Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions. Oncogene 30(10):1213–1228CrossRefPubMed
Clark PE (2007) Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 17(5):331–336CrossRefPubMed
Danilin S, Sourbier C, Thomas L (2009) von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR. Carcinogenesis 30(3):387–396CrossRefPubMed
Danilin S, Sourbier C, Thomas L (2010) Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 31(6):1018–1026CrossRefPubMed
Datta K, Mondal S, Sinha S (2005) Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene 24(53):7850–7858CrossRefPubMed
Denkert C, Weichert W, Winzer KJ (2004a) Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 10(16):5580–5586CrossRefPubMed
Denkert C, Weichert W, Pest S (2004b) Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 64(1):189–195CrossRefPubMed
Denkert C, Koch I, von Keyserlingk N et al (2006) Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 19(9):1261–1269CrossRefPubMed
Dufies M, Giuliano S, Ambrosetti D (2017) Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res 77(5):1212–1226CrossRefPubMed
Epis MR, Barker A, Giles KM (2011) The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 286(48):41442–41454CrossRefPubMedPubMedCentral
Fay J, Kelehan P, Lambkin H (2009) Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J Med Virol 81(5):897–907CrossRefPubMed
Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377(1):114–119CrossRef
Fus ŁP, Pihowicz P, Koperski Ł (2018) High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma. Ann Diagn Pathol 33:40–44CrossRefPubMed
Guo J, Lv J, Chang S (2016) Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget 7(29):45249–45262CrossRefPubMedPubMedCentral
Gupta S, Mahipal A (2013) Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control 20(3):200–210CrossRefPubMed
Heinonen M, Bono P, Narko K (2005) Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65(6):2157–2161CrossRefPubMed
Janakiraman H, House RP, Talwar S et al (2017) Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene 36(22):3137–3148CrossRefPubMed
Jung-Hynes B, Nihal M, Zhong W, Ahmad N (2009) Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284(6):3823–3832CrossRefPubMedPubMedCentral
Kim KY, Li S, Cha JD et al (2012) Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck 34(7):929–936CrossRefPubMed
Kojima K, Fujita Y, Nozawa Y et al (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14):1501–1512CrossRefPubMed
Koljonen V, Böhling T, Haglund C (2008) Expression of HuR in Merkel cell carcinoma and in normal skin. J Cutan Pathol 35(1):10–14PubMed
Kurosu T, Ohga N, Hida Y (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104(5):819–829CrossRefPubMedPubMedCentral
Latorre E, Castiglioni I, Gatto P et al (2014) Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J Pharmacol Exp Ther 349(1):99–106CrossRefPubMed
Liang PI, Li WM, Wang YH (2012) HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer 12:611CrossRefPubMedPubMedCentral
Lim SJ, Kim HJ, Kim JY (2007) Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 26(3):229–234CrossRefPubMed
Lin GL, Ting HJ, Tseng TC et al (2017) Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS ONE 12(10):e0185625CrossRefPubMedPubMedCentral
Liu H, Song X, Hou J et al (2018) Posttranscriptional regulation of human antigen R by miR-133b enhances docetaxel cytotoxicity through the inhibition of ATP-binding cassette subfamily G member 2 in prostate cancer cells. DNA Cell Biol 37(3):210–219CrossRefPubMed
Long BJ, Grigoryev DN, Nnane IP (2000) Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 60(23):6630–6640PubMed
Maeda T, Takahashi A, Hirobe M (2007) Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder. Hinyokika Kiyo 53(4):213–219PubMed
Matsuo T, Miyata Y, Asai A (2017) Green tea polyphenol induces changes in cancer-related factors in an animal model of bladder cancer. PLoS One 12(1):e0171091CrossRefPubMedPubMedCentral
Mitsunari K, Miyata Y, Asai A (2016) Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer. Transl Res 175:116–128CrossRefPubMed
Miyata Y, Watanabe S, Sagara Y (2013) High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer. PLoS One 8(3):e59095CrossRefPubMedPubMedCentral
Miyata Y, Mitsunari K, Akihiro A (2017) Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett 13(2):811–818CrossRefPubMed
Mrena J, Wiksten JP, Thiel A et al (2005) Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 11(20):7362–7368CrossRefPubMed
Nakano M, Shoji S, Higure T (2016) Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer. Mol Clin Oncol 4(6):942–946CrossRefPubMedPubMedCentral
Niesporek S, Kristiansen G, Thoma A (2008) Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 32(2):341–347PubMed
Ning P, Zhong JG2, Jiang F (2016) Role of protein S in castration-resistant prostate cancer-like cells. Endocr Relat Cancer 23(8):595–607CrossRefPubMed
Robinow S, Campos AR, Yao KM (1988) The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. Science 242(4885):1570–1572CrossRefPubMed
Ronkainen H, Vaarala MH, Hirvikoski P, Ristimäki A (2011) HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol 32(3):481–487CrossRefPubMed
Sahin M, Sahin E, Gümüslü S (2009) Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60(2):242–253CrossRefPubMed
Sourbier C, Massfelder T (2006) Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 240(2):170–182CrossRefPubMed
To KK, Leung WW, Ng SS (2015) Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res 338(2):222–231CrossRefPubMed
von Roretz C, Di Marco S, Mazroui R (2011) Turnover of AU-rich-containing mRNAs during stress: a matter of survival. Wiley Interdiscip Rev RNA 2(3):336–347CrossRef
Wang J, Zhao W, Guo Y et al (2009) The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology 76(6):420–429CrossRefPubMed
Wang Y, Wang X, Zhao H et al (2012) Clusterin confers resistance to TNF -alpha -induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemotherapy 24(24):348–357CrossRef
Wang J, Guo Y, Chu H et al (2013) Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci 14(5):10015–10041CrossRefPubMedPubMedCentral
Wenger RH, Stiehl DP, Camenisch G (2005) Integration of oxygen signaling at the consensus HRE. Sci STKE 2005(306):re12PubMed
Xin H, Brown JA, Gong C (2012) Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. Mol Cancer Res 10(1):108–120CrossRefPubMed
Yeap BB, Voon DC, Vivian JP (2002) Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 277(30):27183–27192CrossRef
Yoo PS, Mulkeen AL, Cha CH (2006) Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 12(31):4937–4942CrossRefPubMedPubMedCentral
Yu D, Zhang C, Gui J (2017) RNA-binding protein HuR promotes bladder cancer progression by competitively binding to the long noncoding HOTAIR with miR-1. Onco Targets Ther 10:2609–2619CrossRefPubMedPubMedCentral
Zhang YK, Zhang GN, Wang YJ et al (2016) Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci Rep 6:25694CrossRefPubMedPubMedCentral
Zhou Y, Chang R, Ji W et al (2016) Loss of scribble promotes snail translation through translocation of HuR and enhances cancer drug resistance. J Biol Chem 291(1):291–302CrossRefPubMed
Zhu Z, Wang B, Bi J (2013) Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34(4):2299–2308CrossRefPubMed
Metadata
Title
Multiple functions of HuR in urinary tumors
Authors
Fa Zhang
Zhonglin Cai
Haidi Lv
Wenjuan Li
Mengtian Liang
Xupan Wei
Fenghai Zhou
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2778-2

Other articles of this Issue 1/2019

Journal of Cancer Research and Clinical Oncology 1/2019 Go to the issue

Original Article – Cancer Research

FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma

Original Article – Cancer Research

Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations

Original Article – Cancer Research

Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma

Original Article – Cancer Research

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer

Original Article – Cancer Research

A novel prognostic signature of seven genes for the prediction in patients with thymoma

Original Article – Clinical Oncology

Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits